J M Mubiligi1, B Hedt-Gauthier2, T Mpunga3, N Tapela4, P Okao1, A D Harries5, M E Edginton6, C Driscoll7, L Mugabo1, R Riviello8, L N Shulman9. 1. Partners in Health/Inshuti Mu Buzima, Butaro, Burera District, Rwanda. 2. Partners in Health/Inshuti Mu Buzima, Butaro, Burera District, Rwanda ; Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA. 3. Ministry of Health, Butaro District Hospital, Butaro, Rwanda. 4. Partners in Health/Inshuti Mu Buzima, Butaro, Burera District, Rwanda ; Brigham and Women's Hospital, Boston, Massachusetts, USA. 5. International Union Against Tuberculosis and Lung Disease, Paris, France ; London School of Hygiene & Tropical Medicine, London, UK. 6. International Union Against Tuberculosis and Lung Disease, Paris, France. 7. Partners in Health/Inshuti Mu Buzima, Butaro, Burera District, Rwanda ; Dana Farber Cancer Institute, Boston, Massachusetts, USA. 8. Brigham and Women's Hospital, Boston, Massachusetts, USA. 9. Dana Farber Cancer Institute, Boston, Massachusetts, USA.
Abstract
SETTING: Butaro Cancer Centre of Excellence (BCCOE), Burera District, Rwanda. OBJECTIVES: To describe characteristics, management and 6-month outcome of adult patients presenting with potentially surgically resectable cancers. DESIGN: Retrospective cohort study of patients presenting between 1 July and 31 December 2012. RESULTS: Of 278 patients, 76.6% were female, 51.4% were aged 50-74 years and 75% were referred from other district or tertiary hospitals in Rwanda. For the 250 patients with treatment details, 115 (46%) underwent surgery, with or without chemotherapy/radiotherapy. Median time from admission to surgery was 21 days (IQR 2-91). Breast cancer was the most common type of cancer treated at BCCOE, while other forms of cancer (cervical, colorectal and head and neck) were mainly operated on in tertiary facilities. Ninety-nine patients had no treatment; 52% of these were referred out within 6 months, primarily for palliative care. At 6 months, 6.8% had died or were lost to follow-up. CONCLUSION: Surgical care was provided for many cancer patients referred to BCCOE. However, challenges such as inadequate surgical infrastructure and skills, and patients presenting late with advanced and unresectable disease can limit the ability to manage all cases. This study highlights opportunities and challenges in cancer care relevant to other hospitals in rural settings.
SETTING: Butaro Cancer Centre of Excellence (BCCOE), Burera District, Rwanda. OBJECTIVES: To describe characteristics, management and 6-month outcome of adult patients presenting with potentially surgically resectable cancers. DESIGN: Retrospective cohort study of patients presenting between 1 July and 31 December 2012. RESULTS: Of 278 patients, 76.6% were female, 51.4% were aged 50-74 years and 75% were referred from other district or tertiary hospitals in Rwanda. For the 250 patients with treatment details, 115 (46%) underwent surgery, with or without chemotherapy/radiotherapy. Median time from admission to surgery was 21 days (IQR 2-91). Breast cancer was the most common type of cancer treated at BCCOE, while other forms of cancer (cervical, colorectal and head and neck) were mainly operated on in tertiary facilities. Ninety-nine patients had no treatment; 52% of these were referred out within 6 months, primarily for palliative care. At 6 months, 6.8% had died or were lost to follow-up. CONCLUSION: Surgical care was provided for many cancerpatients referred to BCCOE. However, challenges such as inadequate surgical infrastructure and skills, and patients presenting late with advanced and unresectable disease can limit the ability to manage all cases. This study highlights opportunities and challenges in cancer care relevant to other hospitals in rural settings.
Entities:
Keywords:
Africa; operational research; rural care; solid cancers; surgery
Authors: Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke Journal: Lancet Date: 2007-10-20 Impact factor: 79.321
Authors: Paul Farmer; Julio Frenk; Felicia M Knaul; Lawrence N Shulman; George Alleyne; Lance Armstrong; Rifat Atun; Douglas Blayney; Lincoln Chen; Richard Feachem; Mary Gospodarowicz; Julie Gralow; Sanjay Gupta; Ana Langer; Julian Lob-Levyt; Claire Neal; Anthony Mbewu; Dina Mired; Peter Piot; K Srinath Reddy; Jeffrey D Sachs; Mahmoud Sarhan; John R Seffrin Journal: Lancet Date: 2010-08-13 Impact factor: 79.321
Authors: Ahmedin Jemal; Freddie Bray; David Forman; Meg O'Brien; Jacques Ferlay; Melissa Center; D Maxwell Parkin Journal: Cancer Date: 2012-01-17 Impact factor: 6.860
Authors: Joseph W Carlson; Evan Lyon; David Walton; Wai-Chin Foo; Amy C Sievers; Lawrence N Shulman; Paul Farmer; Vânia Nosé; Danny A Milner Journal: Am J Surg Pathol Date: 2010-01 Impact factor: 6.394
Authors: Imran O Morhason-Bello; Folakemi Odedina; Timothy R Rebbeck; Joe Harford; Jean-Marie Dangou; Lynette Denny; Isaac F Adewole Journal: Lancet Oncol Date: 2013-04 Impact factor: 41.316
Authors: Jean Marie Vianney Dusengimana; Vedaste Hategekimana; Ryan Borg; Bethany Hedt-Gauthier; Neil Gupta; Susan Troyan; Lawrence N Shulman; Ignace Nzayisenga; Temidayo Fadelu; Tharcisse Mpunga; Lydia E Pace Journal: BMC Cancer Date: 2018-06-05 Impact factor: 4.430
Authors: Imco Sibum; Paul Hagedoorn; Markus P G Kluitman; Martijn Kloezen; Henderik W Frijlink; Floris Grasmeijer Journal: Pharmaceutics Date: 2019-12-25 Impact factor: 6.321